Severe disease in historically healthy young children
Fatal outcomes reported in children under 5
Age under 5 and over 65 historically at highest risk
Conjunctivitis less prominently described than in adult U.S. cases
Febrile seizures risk with high fever
Antipyretic management important
Avoid aspirin
Infection control in pediatric settings
Cohorting strategies
Visitor limitation especially siblings
AAP recommendations for influenza in children
2025 to 2026 AAP Technical Report guidance
Background
Epidemiology
Global burden and historical cases
WHO confirmed human cases 1997 to 2015
Predominantly Southeast Asia and Egypt
Overall case fatality rate approximately 50% in historic clades
Systematic review of global cases 1997 to 2015 confirmed high mortality
U.S. outbreak 2024 to 2025
70 confirmed human cases March 2024 to May 2025
Predominantly dairy farm workers and poultry workers
Clade 2.3.4.4b predominant circulating strain
Estimated case fatality 0.7% after adjusting for underreporting
Transmission dynamics
Primary route zoonotic
Direct animal to human transmission
No sustained human-to-human transmission documented with clade 2.3.4.4b
Exposure pathways
Infected poultry and their secretions
Infected dairy cattle and raw milk
Wild birds as reservoir
Occupational risk
Only 36% of exposed farm workers used adequate PPE
Poultry depopulation activities highest risk
Population at risk
Most U.S. clade 2.3.4.4b cases had no underlying conditions
76% of cases without underlying medical conditions
Historically healthy young adults and children at risk for severe disease
Geographic distribution
Cases across multiple U.S. states associated with dairy cattle movement
International cases ongoing in Asia and Africa with historic clades
Pathophysiology
Viral biology
H5N1 influenza A structure
Hemagglutinin H5 subtype with high receptor affinity for lower respiratory tract
Neuraminidase N1 subtype
Highly pathogenic designation based on polybasic cleavage site
Receptor binding differences from seasonal influenza
Preferential binding to alpha-2-3 sialic acid receptors
Predominantly in lower respiratory tract and intestine
Explains tropism for severe pneumonia and GI involvement
Clade evolution
Clade 2.3.4.4b emerged with expanded mammalian host range
Dairy cattle infection unprecedented in H5N1 history
D1.1 genotype reassortant with capability for severe human disease
Disease mechanisms
Cytokine storm
Dysregulated innate immune response
Elevated IL-6, TNF-alpha, interferons
Contributes to multiorgan dysfunction
Direct viral injury
Alveolar epithelial cell destruction
Bilateral pneumonia progressing to ARDS
Rapid radiographic progression within 24 to 48 hours
Systemic spread
Viremia reported in severe cases
CNS involvement via direct invasion or cytokine-mediated injury
Cardiac involvement via direct myocarditis
Therapeutic Considerations
Antiviral resistance landscape
Oseltamivir resistance mutation H274Y
Rare but reported in some H5N1 strains
Zanamivir active against H274Y resistant strains
Resistance testing recommended for treatment failures
Combination antiviral strategy
No definitive clinical trial evidence for combination superiority
Considered for severe disease or suspected resistance
Oseltamivir plus baloxavir under investigation
Immune modulation considerations
Corticosteroids harmful in H5N1
Associated with increased mortality in observational data
Prolonged viral shedding with steroid use
Avoid unless secondary indication is compelling
Convalescent plasma
Limited data in H5N1
Investigational use for severe refractory disease
WHO guidance supports consideration under compassionate use
Pandemic preparedness context
Vaccine stockpile
Audenz H5N1-specific vaccine FDA-approved for high-risk individuals
Seasonal influenza vaccines do not protect against H5N1
Strategic national stockpile considerations
Antiviral stockpile
Strategic national stockpile maintained for neuraminidase inhibitors
WHO advises maintaining antiviral reserves
Surveillance importance
Every case requires full public health investigation
Genomic sequencing to detect concerning mutations
Human-to-human transmission monitoring
Patient Discharge Instructions
copy discharge instructions
H5N1 avian influenza home care instructions
Take oseltamivir exactly as prescribed
Complete the full course even if feeling better
Take with food to reduce stomach upset
Rest and stay well hydrated
Water and clear fluids
Avoid alcohol
Isolate from others while ill
Stay home from work or school until fever-free for 24 hours without antipyretics
Avoid contact with poultry and livestock until cleared by public health
Monitoring requirements
Daily symptom check-in with health department or clinician
Temperature twice daily
Breathing difficulty assessment
All household contacts monitored for 10 days from last exposure
Contact public health if any household member develops symptoms
Do not wait for symptoms to worsen before calling
Warning signs requiring immediate return to emergency department
Difficulty breathing at rest or with minimal activity
Persistent or worsening fever after starting antivirals
Chest pain
Blue or grey colour to lips, face, or fingertips
Confusion, unusual sleepiness, or difficulty waking
Worsening eye redness or visual changes
Coughing up blood
Inability to keep fluids or medications down
A negative rapid flu test does NOT exclude H5N1
Return if symptoms worsen regardless of test result
Prevention instructions
Strict hand hygiene
Wash hands after any animal contact
Before touching face or food
Avoid raw or undercooked poultry, eggs, and unpasteurized dairy
Wear PPE when around poultry or cattle
N95 or equivalent respirator
Eye protection
Gloves
Occupational health follow-up for return-to-farm clearance
Expected recovery
Mild clade 2.3.4.4b illness typically resolves in 1 to 8 days with median 4 days
Follow up within 24 to 48 hours with your clinician
Some fatigue may persist after fever and main symptoms resolve
References
Guidelines and key sources
Primary clinical references
Rolfes MA et al. Human Infections With Highly Pathogenic Avian Influenza A H5N1 Viruses in the United States From March 2024 to May 2025. Nature Medicine 2025
70 U.S. cases characterization
Conjunctival swab diagnostic superiority data
Garg S et al. Highly Pathogenic Avian Influenza A H5N1 Virus Infections in Humans. NEJM 2025
Clinical management guidance
Antiviral recommendations
WHO Writing Committee. Update on Avian Influenza A H5N1 Virus Infection in Humans. NEJM 2008
Mortality predictors including neutropenia plus elevated ALT
LDH as prognostic marker
Supporting literature
Blais-Savoie J et al. Examining the Threat of H5N1 Highly Pathogenic Avian Influenza to Human Health. Chest 2026
Comprehensive clinical review
Severity markers and clade comparison
Adisasmito W et al. Effectiveness of Antiviral Treatment in Human Influenza A H5N1 Infections. Journal of Infectious Diseases 2010
49% mortality reduction with oseltamivir
Benefit up to 6 to 8 days after symptom onset
Lai S et al. Global Epidemiology of Avian Influenza A H5N1 Virus Infection in Humans 1997 to 2015. Lancet Infectious Diseases 2016
Systematic review of global case fatality data
Guidance documents
CDC Yellow Book 2025 Influenza chapter
Travel-associated influenza guidance
PPE recommendations
WHO Rapid Advice Guidelines for Pharmacological Management of Sporadic Human Infection With Avian Influenza A H5N1. Lancet Infectious Diseases 2007
Original WHO antiviral guidance
Oseltamivir dosing framework
AAP Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children 2025 to 2026. Pediatrics 2025
Pediatric antiviral dosing
Weight-based oseltamivir guidance
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.